Rheumatology:类风湿性关节炎应激免疫应答过程

2014-10-29 周泳 丁香园

应激是促进慢性炎症性疾病发展的潜在因素之一,可导致类风湿性关节炎(RA)及银屑病病情进展。荷兰奈梅亨大学医学中心de Brouwer SJ等对RA和银屑病应激状态的免疫应答情况进行研究,该研究结果发表在2014年10月《风湿病学》杂志上。 该研究对病情进展过程中的循环细胞因子水平进行检测,探索性对比急性应激对这些细胞因子的影响,并探讨RA患者、银屑病患者及正常机体中的应激应答反应情况。 纳入研

应激是促进慢性炎症性疾病发展的潜在因素之一,可导致类风湿性关节炎RA)及银屑病病情进展。荷兰奈梅亨大学医学中心de Brouwer SJ等对RA和银屑病应激状态的免疫应答情况进行研究,该研究结果发表在2014年10月《风湿病学》杂志上。

该研究对病情进展过程中的循环细胞因子水平进行检测,探索性对比急性应激对这些细胞因子的影响,并探讨RA患者、银屑病患者及正常机体中的应激应答反应情况。

纳入研究的RA患者、银屑病患者以及健康对照组均进行标准心理社会应激测试(特里尔社会应激测试),并在测试前后对循环细胞因子水平进行检测,检测的细胞因子包括IL-1β, IL-2, IL-4, IL-5,IL-6, IL-7, IL-8, IL-10, IFN-γ 以及 TNF-α。

结果显示,除IL-8外,RA患者在该研究中所检测的细胞因子基线水平均较另外两组显著更高;细胞因子的基线水平校正后,RA患者与银屑病患者和健康对照相比,其应激诱导的IL-1β和IL-2水平更高。

de Brouwer SJ等认为,RA患者的应激免疫应答过程与银屑病及健康对照组不同,而应激与免疫指标及慢性炎症之间的复杂相互作用仍需要进一步探索。

原始出处

de Brouwer SJ1, van Middendorp H2, Stormink C3, Kraaimaat FW3, Joosten I3, Radstake TR3, de Jong EM3, Schalkwijk J3, Donders AR3, Eijsbouts A3, van de Kerkhof PC3, van Riel PL3, Evers AW2.Immune responses to stress in rheumatoid arthritis and psoriasis.Rheumatology (Oxford). 2014 Oct;

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2062504, encodeId=b06f2062504ab, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Mon Aug 17 08:22:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265226, encodeId=16711265226ef, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333763, encodeId=fd211333e63a0, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400207, encodeId=1cdc140020e32, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445093, encodeId=967b1445093cb, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483377, encodeId=ee6d14833e701, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2062504, encodeId=b06f2062504ab, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Mon Aug 17 08:22:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265226, encodeId=16711265226ef, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333763, encodeId=fd211333e63a0, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400207, encodeId=1cdc140020e32, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445093, encodeId=967b1445093cb, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483377, encodeId=ee6d14833e701, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=)]
    2014-10-31 lmm397
  3. [GetPortalCommentsPageByObjectIdResponse(id=2062504, encodeId=b06f2062504ab, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Mon Aug 17 08:22:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265226, encodeId=16711265226ef, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333763, encodeId=fd211333e63a0, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400207, encodeId=1cdc140020e32, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445093, encodeId=967b1445093cb, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483377, encodeId=ee6d14833e701, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2062504, encodeId=b06f2062504ab, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Mon Aug 17 08:22:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265226, encodeId=16711265226ef, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333763, encodeId=fd211333e63a0, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400207, encodeId=1cdc140020e32, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445093, encodeId=967b1445093cb, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483377, encodeId=ee6d14833e701, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2062504, encodeId=b06f2062504ab, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Mon Aug 17 08:22:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265226, encodeId=16711265226ef, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333763, encodeId=fd211333e63a0, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400207, encodeId=1cdc140020e32, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445093, encodeId=967b1445093cb, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483377, encodeId=ee6d14833e701, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=)]
    2014-10-31 hb2008ye
  6. [GetPortalCommentsPageByObjectIdResponse(id=2062504, encodeId=b06f2062504ab, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Mon Aug 17 08:22:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265226, encodeId=16711265226ef, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333763, encodeId=fd211333e63a0, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400207, encodeId=1cdc140020e32, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445093, encodeId=967b1445093cb, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483377, encodeId=ee6d14833e701, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Fri Oct 31 00:22:00 CST 2014, time=2014-10-31, status=1, ipAttribution=)]

相关资讯

Arthritis Care Res:RA早期手骨密度下降可预测侵蚀风险增高

尽管改变病情抗风湿药(DMARDs)的联用使类风湿性关节炎(RA)得到了更好的控制,但仍有一些患者出现进展性侵蚀性病变。早期治疗对患者预后有着积极的意义,研究表明,在“窗口”期对RA进行早期强化治疗可获得良好结局,能减少患者侵蚀性病变及继发残疾的发生。此外,在极早期(前12周)进行RA治疗是12个月时无侵蚀性进展的最好预测指标。对有进展性关节损伤风险的患者做到早期诊断,可让他们提前接受包括生物制剂

NEJM:托法替尼对类风湿性关节炎显示持久的安全性

一项综合的安全性分析显示,托法替尼用于类风湿关节炎(RA)的严重不良事件随着时间的推移仍保持稳定,发生率并未在长期用药患者中出现升高。例如,在接受托法替尼(Tofacitinib )治疗长达6个月的患者中,严重感染发生率(最常见严重不良事件)为2.57/100病人年,在口服这款Janus激酶抑制剂Tofacitinib 超过42个月的患者中,严重感染发生率为1.89/100病人年。最近有关Tofa

PNAS:新型疗法能彻底治愈类风湿性关节炎

类风湿性关节炎是一种引发机体许多关节疼痛炎症的一种疾病,其会引发关节囊肿胀,这种疾病往往会破坏机体的软骨组织和骨质;在世界范围内类风湿性关节炎影响着0.5%至1%的人群的健康,到目前为止医生们已经可以使用多种药物来缓解或者阻断该疾病的发展。近日,刊登在国际杂志PNAS上的一篇研究论文中,来自苏黎世联邦理工学院的研究人员通过研究开发了一种新型疗法,其在治疗患类风湿性关节炎小鼠的功效上可以达到一

PNAS:彻底治愈类风湿性关节炎的新型疗法

类风湿性关节炎是一种引发机体许多关节疼痛炎症的一种疾病,其会引发关节囊肿胀,这种疾病往往会破坏机体的软骨组织和骨质;在世界范围内类风湿性关节炎影响着0.5%至1%的人群的健康,到目前为止医生们已经可以使用多种药物来缓解或者阻断该疾病的发展。近日,刊登在国际杂志PNAS上的一篇研究论文中,来自苏黎世联邦理工学院的研究人员通过研究开发了一种新型疗法,其在治疗患类风湿性关节炎小鼠的功效上可以达到

类风湿性关节炎八类用药

类风湿性关节炎是一种异质性疾病,所有人群均有可能会患上此病,它会引发口腔溃疡、关节脱位、库欣综合征等疾病,类风湿性关节炎的种类很多,表面上表现虽相似,但有不同类型,因而病情轻重、发展、预后、结局都可有所不同,尽管临床上区分这些类型还有困难,但从概念上说,是否所有类风湿性关节炎都一样治疗,就很值得商榷了。 据数据显示,研究人员对532例类风湿性关节炎患者追踪的结果表明,其中症状出现少于6个月者

AAOS 2014:RA不增加同期双侧TKA围手术期并发症发生

严重的类风湿性关节炎(RA)可以引起成人残疾,造成行动和功能障碍。而且相对于骨性关节炎(OA)患者,RA患者双侧膝关节屈曲挛缩、多平面多关节畸形以及较差的健康状况都会给外科医生增加手术难度。我们比较同期双侧膝关节置换术(BTKA)的RA和OA患者的30天死亡率、住院并发症率和发病率、死亡率的风险。 方法:分析该医院1998~2011年间行BTKA的240例RA患者和3680例OA患者资料。统计患